These findings revealed a new mechanism underlying the role of RAS in glucose and lipid metabolism and provided new theoretical support for the clinical application of AT1R blockers in the treatment of obesity-related cardiovascular diseases. The gene discussed is AGTR1; the disease is cardiovascular disorder.